PHILADELPHIA, Sept. 6, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company" or "Hemispherx"), announced that the Company has entered into a new agreement with Armada Health Care, LLC ("Armada") (www.armadahealthcare.com) for the sales/marketing of Alferon N Injection®, its Federal Drug Administration-approved natural interferon, in the U.S. Under this Agreement, the Company will manufacture and supply Alferon N Injection® to physicians and patients through Armada's national network of specialty pharmacies. Specialty Distributor, BioRidge Pharma, LLC ("BRP") will warehouse, ship, and distribute Alferon N Injection® on an exclusive basis for U.S. sales. Armada will also provide start up and ongoing sales and marketing support to the Company.
